The classification of cutaneous lymphomas is multidisciplinary and requires the correlation between clinical, histopathological, immunohistochemical, and molecular diagnostic elements. In this article, we present four different cases of CD30-positive T-cell lymphoma with cutaneous manifestations. We compare cases with definitive diagnosis of papulosis lymphomatoid type C, primary cutaneous anaplastic large T-cell lymphoma, systemic anaplastic large T-cell lymphoma with secondary skin involvement, and mycosis fungoides with large cell transformation, highlighting the importance of clinicopathological correlation to classify these cases.
INTRODUCTION
Cutaneous lymphomas can be classified as primary when
there is no involvement of extra-cutaneous body at the time of diagnosis; or as secondary; when cutaneous infiltration is caused by the dissemination of lymphoma originated in other organs. Among primary extranodal lymphomas, the incidence of primary cutaneous lymphomas (PCLs) is only smaller than gastrointestinal lymphomas. However, they are the most frequent type of T-cell lymphomas. It is crucial to distinguish PCLs from systemic analogs that can secondarily infiltrate the skin. They have different biological behavior, prognosis and therapeutic approach, despite the morphological similarities. PCLs are classified into cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas, according to the source cell lineage. CTCLs correspond to 75%-80% of PCLs, and mycosis fungoides (MF) and its variants account for about 50% of PCLs. 1, 2 CD30-positive lymphoproliferative disorders that affect the skin are also (as the lymphomas in general) divided into primary and secondary. CD30-positive CTCLs account for about 30% of CTCLs, setting the second most prevalent group within the diseases. immunohistochemical expression is not specific for the above conditions, being necessary to point out that the classification of cutaneous lymphomas is only possible through the integration of clinical, histopathological, immunophenotypic, and molecular aspects. 1, 4 The present article reports four cases of CD30-positive lymphoproliferative diseases with skin involvement foccusing the exercise of differential diagnosis between these entities. 
DISCUSSION
The term lymphomatoid papulosis (LP) was first used by Macaulay in 1968 to describe a self-healing rhythmical paradoxical eruption, histologically malignant but clinically benign. Currently, LP is classified as a low-grade CTCL, in the spectrum of cutaneous CD30-positive lymphoproliferative disorders. 4 The characteristic lesions are papules and eventually erythematous/coppery nodules, occurring in outbreaks. Lesions necrotize, ulcerate, and regress in within weeks. 5 Outbreaks may overlap, causing lesions in different evolutionary stages, but the tendency to spontaneous resolution of each individual lesion is the hallmark of this dermatosis. Generally, lesions are widespread, with a predilection for the trunk and limbs.
However, occurrences restricted to an anatomical area may occur.
The number of lesions vary from a few to several hundred, and the symptoms can persist from months to decades. Lymphadenopathy and systemic involvement are not reported. 3,7
Immunohistochemical study shows positivity for CD30 in more than 75% of tumor cells expressing T-cell markers (CD2, CD3, CD5, and CD7), generally T-helper cells (CD4). However, some cases may present memory CD8. 3, 7 Unlike SALCL, cutaneous lymphoma expresses the cutaneous lymphocyte antigen (CLA), which determines tropism of the neoplastic cells to the skin, but does not express the epithelial membrane antigen (EMA) or ALK. MFLCT treatment is a challenge, as it often presents a poor response. The prognosis is particularly poor in patients who have several sites with transformation. In younger patients, the treatment is done with radiation therapy (unifocal transformation) or systemic chemotherapy. In older patients with unifocal transformation, radiotherapy can also be used and occasionally leads to long-term remissions. 19 In case 4, physicians opted for conservative treatment with prednisone and low doses of methotrexate due to the age of the patient, with excellent results.
In this article, we presented 4 different cases of CD30-positive T-cell lymphoma. We emphasize the need for close clinicopathologic correlation for the definitive diagnosis of these lymphomas, highlighting the participation of dermatologists. In case 3, it would be possible to favor a diagnosis of SALCL on pathological grounds due to the positivity for ALK. On the other hand, if clinical and evolutionary evaluation of patients of the other cases were not available, it would not be possible to go beyond a descriptive diagnosis of "cutaneous CD30-positive T-cell lymphoma. q
